Study of URC102 to Assess the Safety and Efficacy in Gout Patients

A Placebo-controlled, Randomized, Double-blind, Multicenter Phase 2 Study to Assess the Efficacy and Safety of URC102 in Gout Patients

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02557126

Enrollment

Registered

2015-09-23

Start date

2015-10-31

Completion date

2016-08-31

Last updated

2017-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout, Hyperuricemia

Brief summary

The purpose of this study is to assess safety, Pharmacokinetics/Pharmacodynamics and Urate Lowering Effect of URC102 in gout patients.

Interventions

DRUGURC102

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

MALE

Age

20 Years to 69 Years

Healthy volunteers

Inclusion criteria

* Diagnosed with gout

Exclusion criteria

* Participated in other clinical study within 12 weeks prior to enrollment, and received an investigational product (including placebo)

Design outcomes

Primary

Measure	Time frame
Trend of serum uric acid reduction rate (%)	2 weeks
Trend of serum uric acid levels (mg/dL)	2 weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026